USP24 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL16647263	1.00	1/20
SCHEMBL17986430	1.00	1/20
SCHEMBL29376701	1.00	1/20
SCHEMBL16647252	0.88	1/20
SCHEMBL18017555	0.86	1/20
SCHEMBL18017557	0.86	1/20
SCHEMBL16647236	0.82	1/20
SCHEMBL23171163	0.76	1/20
SCHEMBL18017556	0.75	1/20
SCHEMBL18017567	0.74	1/20
SCHEMBL18017565	0.73	1/20
SCHEMBL16647235	0.73	1/20
SCHEMBL17986426	0.73	1/20
SCHEMBL20171592	0.71	1/20
SCHEMBL18017561	0.70	1/20
SCHEMBL863519	0.70	1/20
SCHEMBL863520	0.70	1/20
SCHEMBL16647254	0.69	1/20
SCHEMBL17986424	0.69	1/20
SCHEMBL16647223	0.68	1/20

Clinical trials — most relevant to USP24 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients	PHASE4	NOT_YET_RECRUITING
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma	PHASE2	SUSPENDED
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study	PHASE2	WITHDRAWN
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST	PHASE2	COMPLETED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Studying TAK-243 in Patients With Advanced Cancer	PHASE1	RECRUITING
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome	nan	RECRUITING
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure	nan	COMPLETED
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma	nan	COMPLETED
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1	nan	RECRUITING
Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases	nan	UNKNOWN
Prognostic Biomarkers in Tumor Tissue Samples From Young Patients With Neuroblastoma	nan	COMPLETED
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome	nan	RECRUITING
Replacement of Vitamin D in Patients With Active Tuberculosis	nan	COMPLETED
Genetic, Dietary and Environmental Influences on Vitamin D Metabolism	nan	COMPLETED
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
Characterization of Angelman Syndrome	nan	COMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
New Signaling Pathway Targeting Systemic Lupus Erythematosus	nan	UNKNOWN
Molecular Biomarkers Associated With Degenerative Joint Disease in the Knee	nan	COMPLETED
A Natural History Study of Angelman Syndrome	nan	RECRUITING
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis	nan	UNKNOWN
Childhood-Onset Essential Hypertension Natural History Study	nan	RECRUITING
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a USP24 binder may also engage these)

Protein	Name	Similarity
B1AY13	—	1.000	B1AY13 →
O94915	—	1.000	O94915 →
Q9ULT8	—	0.998	Q9ULT8 →
P21359	—	0.997	P21359 →
Q80YV3	—	0.995	Q80YV3 →
Q5T2E6	—	0.995	Q5T2E6 →
FANCI	Fanconi anemia group I protein	0.995	landscape →
P55824	—	0.995	P55824 →
Q5TBA9	—	0.995	Q5TBA9 →
Q69ZR2	—	0.995	Q69ZR2 →
A5GFY4	—	0.995	A5GFY4 →
Q5F3M0	—	0.995	Q5F3M0 →
E9Q8I9	—	0.995	E9Q8I9 →
DNAJC13	DnaJ homolog subfamily C member 13	0.994	landscape →
LRBA	Lipopolysaccharide-responsive and beige-like anchor protein	0.994	landscape →
Q5ZL91	—	0.994	Q5ZL91 →
Q8IV36	—	0.994	Q8IV36 →
Q04690	—	0.993	Q04690 →
Q6DCT2	—	0.993	Q6DCT2 →
Q9NVH2	—	0.993	Q9NVH2 →
Q6PIY5	—	0.993	Q6PIY5 →
Q10LJ0	—	0.993	Q10LJ0 →
Q6PD19	—	0.993	Q6PD19 →
Q3UHQ6	—	0.992	Q3UHQ6 →
Q80TR8	—	0.992	Q80TR8 →
P97526	—	0.992	P97526 →
Q9P2D8	—	0.992	Q9P2D8 →
Q14D04	—	0.992	Q14D04 →
Q922L6	—	0.992	Q922L6 →
Q6ZS30	—	0.992	Q6ZS30 →